Pharmacologic therapies are essential in the management of patients with cardiovascular and thrombotic disorders because they are able to modify components of the pathways involved in these disorders. Nevertheless, responses to different drugs vary significantly, and the best clinical outcome frequently involves a delicate balance between risk and benefit. The field of pharmacogenomics has led to the emergence of individualized medicine that has revolutionized modern medical practice, allowing for a deeper understanding of pathophysiology, increased diagnostic specificity and better markers for risk stratification, as well as an enhanced potential for gene therapy. Management of drugs prescribed to treat cardiovascular abnormalities have been shown to benefit from pharmacogenetics, and our focus in this review will be on the pharmacogenetics related to some of the more common drugs that fall into this category.
|Original language||English (US)|
|Title of host publication||Pharmacogenomics in Clinical Therapeutics|
|Publisher||John Wiley and Sons|
|Number of pages||29|
|State||Published - Feb 24 2012|
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)